Short Interest in MDxHealth SA (NASDAQ:MDXH) Declines By 49.7%

MDxHealth SA (NASDAQ:MDXH) was the target of a large drop in short interest in May. As of May 29th, there was short interest totaling 457,830 shares, a drop of 49.7% from the May 14th total of 910,289 shares. Currently, 0.9% of the company’s stock are sold short. Based on an average daily volume of 718,711 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Investors Weigh In On MDxHealth

Institutional investors have recently added to or reduced their stakes in the company. Intesa Sanpaolo Wealth Management bought a new position in MDxHealth during the fourth quarter valued at about $36,000. GSA Capital Partners LLP bought a new stake in MDxHealth in the 3rd quarter valued at $48,000. Lido Advisors LLC bought a new stake in MDxHealth in the 3rd quarter valued at $48,000. Citadel Advisors LLC raised its stake in shares of MDxHealth by 30.6% in the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock valued at $228,000 after buying an additional 11,456 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth in the 3rd quarter valued at $53,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on MDXH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. TD Cowen reaffirmed a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. BTIG Research decreased their price target on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Lake Street Capital lowered their price objective on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $4.63.

MDxHealth Trading Down 7.6%

Shares of MDXH stock opened at $0.54 on Friday. The firm has a market capitalization of $26.84 million, a P/E ratio of -0.83 and a beta of 1.36. MDxHealth has a 1 year low of $0.51 and a 1 year high of $5.33. The firm’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $2.74.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $30.89 million. MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. Equities research analysts anticipate that MDxHealth will post -0.6 EPS for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.